Trial Profile
A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Dendritic cell vaccines
- Indications Malignant melanoma
- Focus Pharmacodynamics; Pharmacogenomic
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Planned End Date changed from 6 Jun 2019 to 31 Jul 2019.
- 08 Jun 2018 Planned primary completion date changed from 6 Jun 2018 to 11 Jul 2018.